
|Articles|March 26, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
The Rationale for Immunotherapy in NSCLC
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
Advertisement
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
<<<
Articles in this issue
over 10 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersover 10 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayover 10 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaover 10 years ago
Major Programs Under Way in Immuno-Oncologyover 10 years ago
PD-1 Inhibitors for Melanomaover 10 years ago
Immunotherapy in GU CancersAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































